1835 related articles for article (PubMed ID: 16458289)
1. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
2. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
Sanz MJ; Cortijo J; Morcillo EJ
Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015
[TBL] [Abstract][Full Text] [Related]
3. [Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].
Tatlicioğlu T
Tuberk Toraks; 2008; 56(4):472-84. PubMed ID: 19123088
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
[TBL] [Abstract][Full Text] [Related]
6. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Antoniu SA
Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Lipworth BJ
Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
[TBL] [Abstract][Full Text] [Related]
8. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE
Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865
[TBL] [Abstract][Full Text] [Related]
9. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
Dastidar SG; Rajagopal D; Ray A
Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
[TBL] [Abstract][Full Text] [Related]
11. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Karish SB; Gagnon JM
Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
[TBL] [Abstract][Full Text] [Related]
12. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
Banner KH; Trevethick MA
Trends Pharmacol Sci; 2004 Aug; 25(8):430-6. PubMed ID: 15276712
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
14. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Smith VB; Spina D
Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
16. The potential of PDE4 inhibitors in asthma or COPD.
Spina D
Curr Opin Investig Drugs; 2000 Oct; 1(2):204-13. PubMed ID: 11249575
[TBL] [Abstract][Full Text] [Related]
17. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Huang Z; Dias R; Jones T; Liu S; Styhler A; Claveau D; Otu F; Ng K; Laliberte F; Zhang L; Goetghebeur P; Abraham WM; Macdonald D; Dubé D; Gallant M; Lacombe P; Girard Y; Young RN; Turner MJ; Nicholson DW; Mancini JA
Biochem Pharmacol; 2007 Jun; 73(12):1971-81. PubMed ID: 17428447
[TBL] [Abstract][Full Text] [Related]
18. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of a novel, orally active PDE4 inhibitor.
Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
[TBL] [Abstract][Full Text] [Related]
20. Type 4 phosphodiesterase-dependent pathways: role in inflammatory processes.
Jacob C; Martin-Chouly C; Lagente V
Therapie; 2002; 57(2):163-8. PubMed ID: 12185965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]